Long-Acting GLP-2 Analogue (Glepaglutide) and Short Bowel Syndrome

Glepaglutide is a long-acting GLP-2 (glucagon-like peptide-2) analogue designed to improve intestinal function and absorption in patients with short bowel syndrome (SBS). SBS is a condition characterized by the loss of significant portions of the small intestine, leading to malabsorption and dependency on parenteral support (PS) for nutrition and hydration.

Mechanism of Action:

GLP-2 is a naturally occurring gut hormone that plays a crucial role in intestinal growth, repair, and function. Glepaglutide, as a synthetic analogue, mimics the action of GLP-2, stimulating intestinal adaptation and regeneration. It promotes:

1. Mucosal Growth: Glepaglutide enhances the regeneration of the intestinal lining, which improves nutrient absorption and fluid retention.

2. Blood Flow: It increases intestinal blood flow, supporting better nutrient delivery and absorption.

3. Barrier Function: The drug strengthens the intestinal barrier, reducing the risk of bacterial translocation and infection.

4. Reduction in Gastric Motility: Glepaglutide slows intestinal transit time, allowing for better absorption of nutrients and fluids.

Clinical Benefits in Short Bowel Syndrome:

1. Reduction in Parenteral Support (PS) Dependency:

• Twice-weekly (TW) dosing of glepaglutide significantly reduces the volume of PS required. Patients on 10 mg TW achieved a mean reduction of −5.13 liters/week compared to −2.85 liters/week in the placebo group, demonstrating a significant treatment difference of −2.28 liters/week (P = 0.0039).
• Once-weekly (OW) dosing showed smaller, nonsignificant reductions (−0.91 liters/week; P = 0.27), suggesting TW dosing is more effective.

2. Clinically Meaningful Reductions:

• 65.7% of TW-treated patients achieved at least a 20% reduction in PS, compared to 38.9% on placebo (P = 0.0243). This indicates substantial improvement in intestinal absorption and functionality.

3. Improved Autonomy:

• Over half (51.4%) of TW-treated patients were able to reduce their PS frequency by at least one day per week, compared to 19.4% of placebo-treated patients (P = 0.0043). This improvement in autonomy significantly enhances the quality of life.

4. Complete PS Independence:

• 14% of TW-treated patients achieved enteral autonomy (complete independence from PS), compared to 11% on OW dosing and none in the placebo group. This underscores glepaglutide's potential to restore natural intestinal function.

5. Sustained Efficacy:

• TW dosing showed early improvements in PS reduction by week 12, which were sustained through week 24. This benefit was consistent across patients with or without colon-in-continuity, indicating broad applicability.

6. Improved Patient-Reported Outcomes:

• Nearly half (48.6%) of TW-treated patients rated themselves as “much” or “very much improved,” compared to only 5.6% in the placebo group (P < 0.0001). This highlights the drug’s impact on overall quality of life.

7. Biological Evidence of Intestinal Adaptation:

• Serum citrulline levels, a marker of mucosal growth and intestinal adaptation, increased by 47% with TW dosing versus 19% with OW dosing and 5% with placebo (P = 0.0139). This confirms glepaglutide's ability to enhance mucosal regeneration.

Safety and Tolerability:

Glepaglutide demonstrated a favorable safety profile:

• Most adverse events were mild to moderate, including injection site reactions, stoma swelling, and gastrointestinal discomfort.
• Serious adverse events were primarily related to PS itself, not the drug.
• Anti-drug antibodies were detected in 87% of treated patients but had no impact on efficacy or safety, affirming long-term therapeutic stability.

Summary:

Glepaglutide, as a long-acting GLP-2 analogue, offers significant benefits for patients with SBS by improving intestinal absorption, reducing PS dependency, and enhancing autonomy and quality of life. TW dosing is particularly effective, showing early, sustained, and clinically meaningful improvements. The drug is well-tolerated, with minimal safety concerns, and demonstrates biological evidence of intestinal adaptation. This makes glepaglutide a promising therapeutic option for managing SBS and restoring natural intestinal function.